Sena, Arlene C. published the artcileA systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy, Recommanded Product: N1,N2-Dibenzylethane-1,2-diamine, the publication is BMC Infectious Diseases (2015), 479/1-479/15, database is CAplus and MEDLINE.
Syphilis remains a global public health threat and can lead to severe complications. In addition to resolution of clin. manifestations, a reduction in nontreponemal antibody titers after treatment is regarded as “proof of cure.” However, some patients manifest < 4-fold decline (“serol. non-response”) or persistently pos. nontreponemal titers despite an appropriate decline (“serofast”) that may represent treatment failure, reinfection, or a benign immune response. To delineate these treatment phenomena, we conducted a systematic review of the literature regarding serol. outcomes and associated factors among HIV-infected and -uninfected subjects. Six databases (PubMed, Embase, CINAHL, Web of Science, Scopus, and BIOSIS) were searched with no date restrictions. Relevant articles that evaluated serol. treatment responses and correlates of serol. cure (¡Ý fourfold decline in nontreponemal titers) were included. We identified 1693 reports in the literature, of which 20 studies met selection criteria. The median proportion of patients who had serol. non-response was 12.1 % overall (interquartile range, 4.9-25.6), but varied depending on the time points after therapy. The serofast proportion could only be estimated from 2 studies, which ranged from 35.2-44.4 %. Serol. cure was primarily associated with younger age, higher baseline nontreponemal titers, and earlier syphilis stage. The relationship between serol. cure and HIV status was inconsistent; among HIV-infected patients, CD4 count and HIV viral load was not associated with serol. cure. Serol. non-response and the serofast state are common syphilis treatment outcomes, highlighting the importance of determining the immunol. and clin. significance of persistent nontreponemal antibody titers after therapy.
BMC Infectious Diseases published new progress about 140-28-3. 140-28-3 belongs to catalysis-chemistry, auxiliary class Benzenes, name is N1,N2-Dibenzylethane-1,2-diamine, and the molecular formula is C9H7NO3, Recommanded Product: N1,N2-Dibenzylethane-1,2-diamine.
Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia